This just in from Forbes via PharmaGossip. Big pharma has been counting on emerging markets to help it fill in revenue gaps from big selling products that have been steadily coming off patent. Guess what?
According to the Forbes piece, citing Ernst & Young, big pharma's revenue estimates have been a tad overstated -- by a mere $47 B. It seems emerging markets are competitive too and local competitors can sell generics at 50% or less the price. Not to mention local governments are looking to save money and actually support sales fo generics. Who'd thunk?
Oh well. Stuff happens.
Posted by Bruce Lehr Sep 4th 2012.